Pilon D, et al. - Omalizumab is approved in patients with moderate-to-severe allergic asthma with symptoms uncontrolled, despite the mainstay therapy. In this current study, using electronic medical records, it was demonstrated that omalizumab was related to beneficial impacts on asthma control and symptoms and the likelihood of requiring new oral corticosteroid prescriptions in patients with uncontrolled moderate-to-severe allergic asthma. Not reaching the statistical significance, a trend of improved lung function and lower likelihood of requiring high- and medium-dose inhaled corticosteroid was also observed.